Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.04.19	Regeneron To Invest $800 Mln In Alnylam; To Jointly Develop RNAi Therapeutics (RTTNews)
26.03.19	Biotech Stocks Facing FDA Decision In April (RTTNews)
08.03.19	Regeneron And Sanofi Say FDA Accept For Priority Review SBLA For Dupixent (RTTNews)
01.03.19	Regeneron Says CHMP Recommends Approval Of Dupixent For Asthma Indication (RTTNews)
27.02.19	Biotech Stocks Facing FDA Decision In March (RTTNews)
25.02.19	Amgen: Delaware Jury Upholds Validity Of Two Patents Related To PCSK9 Antibodies (RTTNews)
11.02.19	Sanofi, Regeneron Offer Praluent At 60% Reduced U.S. List Price - Quick Facts (RTTNews)
06.02.19	Regeneron Pharmaceuticals Q4 adjusted earnings Beat Estimates (RTTNews)
07.01.19	Regeneron, Sanofi Select Two Clinical-stage Antibodies For Ongoing Collaboration (RTTNews)
04.01.19	Regeneron Posting Strong Gain On Upgrade By Guggenheim (RTTNews)
06.11.18	Regeneron Pharmaceuticals Q3 adjusted earnings Beat Estimates (RTTNews)
06.11.18	Regeneron : FDA Grants Priority Review For Dupixent (RTTNews)
25.10.18	Regeneron: Eylea Phase 3 Panorama Trial Meets Primary, Secondary Endpoints (RTTNews)
22.10.18	Regeneron Pharma: FDA Approves Asthma Indication For Dupixent - Quick Facts (RTTNews)
22.10.18	FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch (RTTNews)
16.10.18	Regeneron : Dupixent Shows Positive Results In Two Phase 3 Trials On CRSwNP (RTTNews)
28.09.18	Biotech Stocks Facing FDA Decision In October (RTTNews)
13.09.18	ADIL On Track, PGNX Slumps On Phase III Study Failure, VNDA On Watch (RTTNews)
12.09.18	Sanofi And Regeneron : FDA To Review SBLA For Praluent Injection (RTTNews)
12.09.18	FOMX Soars On Acne Trial Data, GLPG Abuzz, ACRX To Face FDA Panel In Oct. (RTTNews)
19.08.18	Week Ahead In Pharmaceuticals: 7 Stocks To Watch (TNXP, REGN, KALA...) (RTTNews)
17.08.18	Regeneron Pharma: FDA Okays EYLEA Injection SBLA In Wet AMD (RTTNews)
16.08.18	Teva And Regeneron Announce Positive Phase 3 Fasinumab Results (RTTNews)
14.08.18	MBIO & Bubble Boy Disease Gene Therapy, Busy Months Ahead For EIGR, UMRX (RTTNews)
13.08.18	Regeneron Pharma: FDA Issues Response Letter On SBLA For EYLEA - Quick Facts (RTTNews)
11.08.18	Week Ahead In Pharmaceuticals: 5 Stocks To Watch (REGN, PFE, ALT...) (RTTNews)
06.08.18	Regeneron, Bluebird Bio Announce Collaboration - Quick Facts (RTTNews)
04.08.18	Week Ahead In Pharmaceuticals - 10 Stocks To Watch (ALNY, INSM, PRTK...) (RTTNews)
02.08.18	Regeneron Showing Strong Move To The Upside (RTTNews)
02.08.18	Regeneron Pharmaceuticals Q2 adjusted earnings Beat Estimates (RTTNews)
26.07.18	Biotech Stocks Facing FDA Decision In August (RTTNews)
06.06.18	Regeneron, Zoetis Announce Research Collaboration - Quick Facts (RTTNews)
06.06.18	Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health (PR Newswire)
04.06.18	New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma (PR Newswire)
04.06.18	New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
31.05.18	Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak (PR Newswire)
21.05.18	New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma (PR Newswire)
21.05.18	New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma (PR Newswire)
18.05.18	Regeneron Announces Upcoming Investor Conference Presentation (PR Newswire)
16.05.18	Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO (PR Newswire)
16.05.18	Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis (PR Newswire)
16.05.18	Regeneron, Sanofi: Phase 3 Dupixent Trial Meets Primary, Key Secondary Endpoints (RTTNews)
16.05.18	Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis (PR Newswire)
03.05.18	Regeneron Pharmaceuticals Q1 adjusted earnings Beat Estimates (RTTNews)
03.05.18	Regeneron Reports First Quarter 2018 Financial and Operating Results (PR Newswire)
02.05.18	DocPanel Announces Partnership with the University of Southern California Keck School of Medicine (PR Newswire)
01.05.18	2018 Global Channel Report Reveals Clients Attacked Mostly Through Privileged Accounts (PR Newswire)
01.05.18	Sanofi, Renegeron To Lower Net Price Of Praluent Injection - Quick Facts (RTTNews)
01.05.18	Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients (PR Newswire)
01.05.18	Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

31.10.24

NASDAQ-Handel NASDAQ 100 schlussendlich in Rot

31.10.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone

31.10.24

NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell

31.10.24

Zurückhaltung in New York: So performt der NASDAQ 100 aktuell

31.10.24

Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus